No­var­tis bol­sters Plu­vic­to's case in prostate can­cer with PhI­II re­sults

The prog­no­sis is poor for metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) pa­tients. No­var­tis wants to change that by mak­ing its re­cent­ly ap­proved Plu­vic­to avail­able to pa­tients ear­li­er in their course of treat­ment.

The Swiss phar­ma gi­ant un­veiled Phase III re­sults Mon­day sug­gest­ing that Plu­vic­to was able to halt dis­ease pro­gres­sion in cer­tain prostate can­cer pa­tients when ad­min­is­tered af­ter an­dro­gen-re­cep­tor path­way in­hibitor (ARPI) ther­a­py, but with­out pri­or tax­ane-based chemother­a­py. The drug is cur­rent­ly ap­proved for pa­tients af­ter they’ve re­ceived both ARPI and chemo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER